骨髓间质干细胞减轻收缩期高血压的心肌损伤

Bone marrow mesenchymal stem cell transplantation alleviates myocardial injury due to systolic hypertension

BACKGROUND:Mesenchymal stem cells can be used to treat a variety of injuries, but little is known about their effect on systolic hypertension. OBJECTIVE:To study the therapeutic effect of bone marrow mesenchymal stem cells on systolic hypertension rats. METHODS:Twenty-four rats were randomized equally into control, model and cell transplantation groups. A rat model of systolic hypertension was made by injection of vitamin K and warfarin sodium in the model and cell transplantation groups. Rats in the cell transplantation group were given injection of bone marrow mesenchymal stem cells into the left ventricle, while those in the other two groups given normal saline. RESULTS AND CONCLUSION:Compared with the model group, bone marrow mesenchymal stem cells could reduce left ventricular mass index, increase cardiac tissue type I collagen volume fraction, collagen volume fraction and perivascular collagen volume fraction, but the ratio of end-diastolic volume/body weight did not change significantly. These findings indicate that bone marrow mesenchymal stem cell transplantation can reduce myocardial hypertrophy and cardiac fibrosis in systolic hypertension rats.